Partner Stephen Aschettino was quoted in an ISO & Agent article “Merchants in Legal Hot Water After EMV Shift,” on July 5, 2016. The article discussed how some merchants are facing consumer lawsuits stemming from the introduction of EMV-chip card security at the point of sale. For example, a Wendy’s customer filed a class action against the restaurant alleging that it failed to protect customers’ credit card information, as well as other personally identifiable information. “I think they’re just trying to show that Wendy’s failure to use the EMV chip is some form of negligence. If my analysis is correct, I think that’s very different than the liability shift issue that we in the industry are very worried about.” He continued to explain a lawsuit filed by B&R Supermarket against most of the major card networks and issuers claiming thousands of dollars in losses because of the EMV shift. “Depending on the magnitude of the chargebacks and resources of the merchants, some merchants may be willing to challenge those rules. I do foresee there will be more litigation going forward on these issues.”
Related News
August 13, 2025
In the News
Leigh Riley on Elevating Partner Development with Foley's PEAK Program – 'We can't stop learning'
Foley & Lardner LLP partner Leigh Riley appeared on the Big Law Life podcast to share how Foley is redefining professional development to meet the needs of the firm's partners and the demands of modern legal practice.
August 8, 2025
In the News
Gregory Husisian and David Simon Uncover the High Stakes of Tariff Evasion
Foley & Lardner LLP partners Gregory Husisian and David Simon are featured for their insights on how the U.S. government is cracking down on tariff evaders in the Newsweek article, "America Is Making Billions From Catching 'Tariff Cheaters.'"
August 7, 2025
In the News
Kyle Faget Weighs in on Trump Pharma Tariffs
Foley & Lardner LLP partner Kyle Faget assessed the Trump administration's implementation of import tariffs on the pharmaceutical industry in the Pharma Life Sciences article, "Trump's pharma import tariffs threaten drug pricing, generics."